# QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

> **NCT02384954** · PHASE1,PHASE2 · TERMINATED · sponsor: **Altor BioScience** · enrollment: 43 (actual)

## Conditions studied

- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** N-803

## Key facts

- **NCT ID:** NCT02384954
- **Lead sponsor:** Altor BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-17
- **Primary completion:** 2020-12-13
- **Final completion:** 2020-12-13
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Change in drug product development strategy.
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02384954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02384954, "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT02384954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*